AOTI’s Topical Wound Oxygen Therapy shows 64.8% complete healing in large multicentre cohort

About this episode

Mike Griffiths discusses the findings of a multicentre study on AOTI's Topical Wound Oxygen therapy and its effectiveness in healing chronic wounds.

AOTI Inc. CEO Mike Griffiths joined Steve Darling from Proactive to highlight key findings from a newly published multicentre retrospective cohort study in the Journal of Vascular Surgery–Vascular Insights, evaluating the effectiveness of the company’s Topical Wound Oxygen (TWO) therapy in treating chronic lower extremity wounds. Griffiths explained that the study demonstrated a high rate of complete and durable healing using AOTI’s intermittent TWO2® therapy as an adjunct to standard of care. The therapy was applied to hard-to-heal wounds that had previously failed to respond to other advanced treatments for an average of seven months, underscoring the complexity of the patient population. The large-scale study included 3,126 patients across a wide range of wound types, including diabetic foot ulcers, venous leg ulcers, arterial ulcers, and atypical wounds. The findings build on prior randomized clinical trials and real-world evidence supporting the therapy’s effectiveness, particularly in diabetic foot ulcers. Results showed that 64.8% of patients (2,027 individuals) achieved complete wound healing, with an average healing time of 4.2 months—despite wounds having persisted for…

People in this episode

Host: Steve Darling

Guest: Mike Griffiths

Topics covered

• wound healing
• medical therapy
• clinical study
• chronic wounds
• patient outcomes

Keywords

• AOTI
• Topical Wound Oxygen
• TWO2 therapy
• wound healing
• clinical study
• patient outcomes
• diabetic foot ulcers
• venous leg ulcers
• healing rate

Mentioned in this episode

Organizations: AOTI Inc., Journal of Vascular Surgery–Vascular Insights

Products: Topical Wound Oxygen (TWO) therapy, TWO2® therapy

Places: diabetic foot ulcers, venous leg ulcers, arterial ulcers, atypical wounds

More episodes of Proactive - Interviews for investors

• Regan Capital CIO on bond market opportunities in a rising rate environment · June 12, 2026 · 6 min
• Light Science Technologies lifts capacity 50% with new SMT line and global client win · June 12, 2026 · 5 min
• Poolbeg Pharma launches POLB 001 TOPICAL trial to tackle CAR-T side effects · June 12, 2026 · 4 min
• Lumos Diagnostics expands FebriDx adoption across 100+ US healthcare sites with CLIA Waiver · June 11, 2026 · 8 min
• Flow Metals advances drill-ready Yukon gold project while expanding Copper exploration in B.C. · June 11, 2026 · 6 min
• Midstream energy sector positioned for growth as LNG and AI drive demand · June 11, 2026 · 7 min